ThyroSeq Molecular marker testing ( CBL Path Inc) on indeterminate thyroid nodules turned up medullary carcinoma MCT and parathyroid lesions in 1% of 5000 indeterminate results. With the low accuracy of cytology to diagnose both rare diseases in the thyroid the marker test can help. MCT had RET,KRAS, and BRAF. Surgery in 13 confirmed MCT. Parathyroid profile was found in 26 and 10 that went to surgery confirmed the diagnosis.
We use ThyroSeq2 and ThyGenX molecular markers in my practice.
Richard Guttler MD,FACE,ECNU